

**MEETING MINUTES  
OF THE  
CENTERS FOR MEDICARE AND MEDICAID SERVICES  
MEDICARE EVIDENCE DEVELOPMENT & COVERAGE  
ADVISORY COMMITTEE**

**January 25, 2012**

**Centers for Medicare and Medicaid Services  
7500 Security Boulevard  
Baltimore, Maryland**

**Medicare Evidence Development & Coverage Advisory Committee**

**January 25, 2012**

**Attendees**

**Chairperson**

Clifford Goodman, PhD

**Vice-Chair**

Steve E. Phurrough, MD

**Voting Members**

Jeptha P. Curtis, MD

Philip B. Gorelick, MD, MPH

Mark A. Hlatky, MD

Pearl Moore, RN, MN, FAAN

William R. Phillips, MD, MPH

Art Sedrakyan, MD, PhD

Robert L. Steinbrook, MD

Robert K. Zeman, MD

**Industry Representative**

Peter Juhn, MD, MPH

**Guest Panel Members**

Larry B. Goldstein, MD, FAAN, FAHA

A. Mark Fendrick, MD

J. David Spence, BA, MBA, MD, FRCPC, FAHA

**CMS Liaison**

Louis Jacques, MD

Jyme Schafer, MD

**Invited Guest Speakers**

Anne L. Abbott, MD, PhD

Thomas G. Brott, MD

Mark D. Grant, MD, MPH

William A. Gray, MD

Wesley S. Moore, PhD

**Executive Secretary**

Maria Ellis

**Wednesday, January 25, 2012, 8:10 a.m.**

The Medicare Evidence Development & Coverage Advisory Committee met on January 25, 2012, to discuss the evidence, hear presentations and public comment, and make recommendations concerning the available evidence regarding the management of carotid atherosclerosis and its health outcomes.

The meeting began with a reading of a conflict of interest statement, welcoming remarks, comments from the director of the Office of Clinical Standards and Quality, and an introduction of the Committee.

**CMS Presentation and Voting Questions.** A CMS representative presented the panel and audience with a history of CMS coverage for carotid artery stenting and endarterectomy, reviewed some of the relevant definitions for the discussion and voting, and then read the voting and discussion questions that would be considered by the panel.

**Presentation of Technology Assessment.** The panel heard a presentation from Dr. Mark Grant based on the technology assessment performed by the Blue Cross and Blue Shield Association Technology Evaluation Center.

**Presentations by Invited Guest Speakers.** The panel heard presentations from four invited guest speakers. The speakers addressed assessment of risk of adverse events and other outcomes associated with alternative interventions for managing carotid atherosclerosis; presented findings of clinical trials, other studies, and related analyses; and shared their views regarding matters to be addressed by the voting and discussion questions before the panel.

**Scheduled Public Comments.** The panel heard from 13 scheduled speakers, including clinicians, study designers and participants, and professional society representatives.

**Open Public Comments.** The panel heard from five members of the public, including clinicians and manufacturer representatives.

**Questions to Presenters.** The panel was given the opportunity to pose questions to the presenters.


**Initial Open Panel Discussion.** The panel conducted an extensive discussion on each of the voting questions posed by CMS. The discussion included input from the chair and vice-chair, all members of the panel, presenters as requested by members of the panel, and CMS representatives.

**Formal Remarks and Voting Questions.** The panel turned its attention to the voting questions, with additional discussion before votes on each question. The results of the voting were recorded on electronic devices, announced to the public, and recorded manually.

**Final Open Panel Discussion.** After completion of the voting questions, each panelist was given the opportunity to express opinions regarding research gaps and unmet needs in the area of carotid artery disease, and to comment on their overarching view on the state of the evidence in this area based on the information presented during the meeting.

**Adjournment.** The meeting adjourned at 4:30 p.m.

I certify that I attended the meeting  
of the Medicare Evidence Development  
& Coverage Advisory Committee on  
January 25, 2012, and that these minutes  
accurately reflect what transpired.

  
\_\_\_\_\_  
Maria A. Ellis  
Executive Secretary, MEDCAC, CMS

I approve the minutes of this meeting  
as recorded in this summary.



Clifford Goodman, Ph.D.  
Chairperson